Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,506JPY
17 May 2019
Change (% chg)

¥30 (+2.03%)
Prev Close
¥1,476
Open
¥1,526
Day's High
¥1,532
Day's Low
¥1,503
Volume
7,654,000
Avg. Vol
6,222,755
52-wk High
¥2,056
52-wk Low
¥1,356

Select another date:

Thu, Apr 25 2019

Photo

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications, the U.S. Justice Department said on Thursday.

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates

Astellas Pharma and Eli Lilly and Co must face a whistleblower lawsuit accusing them of knowingly underpaying rebates they owed to state Medicaid programs, a federal judge has ruled.

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Astellas Pharma gets U.S. nod for blood cancer treatment

Nov 28 Japan's Astellas Pharma Inc on Wednesday received approval from the U.S. Food and Drug Administration for its blood cancer treatment, according to the regulator's website https://bit.ly/2SjB8CL.

Select another date: